Aclarion, Inc. ACON 深 沪
已收盘 10-31 16:00:00 美东时间
7.76
+0.030
+0.39%
华盛通- 最 高7.8875
- 今 开7.8875
- 成交量 1.47万股
- 最 低 7.73
- 昨 收 7.73
- 总市值 451.94万
- 52周最高 3499.5105
- 市盈率 静 --
- 换手率 2.53%
- 52周最低 6.20
- 委 比 -72.97%
- 总股本 58.24万
- 历史最高 586116.00
- 量 比 0.59
- 振 幅 2.04%
- 历史最低 7.73
- 每 手 1
- 风险率 588.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Beyond Silicon Valley To Scotch: AI Funding Surges
Explore AI funding trends beyond Silicon Valley. Discover investments spanning biotech & enterprise software, to alcohol & insurance.
10-22 22:34
港股早知道 | 紫金黄金国际Q3净利润3.85亿美元；中国人寿预计今年前三季度净利同比增长50%-70%
紫金黄金国际Q3净利润3.85亿美元；中国人寿预计今年前三季度净利同比增长50%-70%；赣锋锂业拟以约6.64亿元收购深圳易储44.2361%股权>>
10-20 07:58
洲际船务附属拟1710万美元出售一艘船舶
洲际船务（02409）发布公告，于2025年10月17日，卖方Seacon Manila Ltd（本公司的间接全资附属公司）、买方BULK EXPORTS...
10-20 07:53
洲际船务附属拟租赁三艘散货船
洲际船务（02409）发布公告，于2025年10月16日（联交所交易时段后），（1）各租船人（为本公司三间间接全资附属公司，SEACON ATLANTA ...
10-17 08:28
Aclarion Highlights Accelerating Growth, $13.3M Cash Balance, And AI-Driven Biomarker Validation Progress
Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility for continued commercial growthNociscan scan volumes increase +89% year-over-year with third
10-14 18:11
Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst
Aclarion, Inc. reported strong financials, market adoption, and clinical trial progress in its Q3 2025 update. The company has a debt-free balance sheet with $13.3 million in cash, supporting commercial growth. Nociscan scan volumes increased 89% year-over-year, marking three consecutive quarters of record utilization across U.S., U.K., and E.U. markets. The CLARITY pivotal trial is advancing on schedule with early 3-month readouts expected in Q2...
10-14 10:09
默克「西妥昔单抗」国内获批新适应症
（来源：抗体圈） 截图来源：默克官微 爱必妥此次新适应症的获批是基于一项随机、多中心、全球 III 期临床试验 BEACON CRC 以及在中国的桥接...
10-13 16:38
Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference
Aclarion, Inc. announced its participation in the ISPN Annual Meeting in London, highlighting the use of Nociscan®, a SaaS platform leveraging MRI spectroscopy and AI to identify chronic low back pain biomarkers. Over 266 million people worldwide suffer from chronic low back pain, and Nociscan® aims to become the gold standard for diagnosis by providing objective biomarker data. Experts emphasized the critical role of disc chemistry in diagnosing...
10-13 10:00
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options If you purchased or...
10-11 08:05
Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
<p>Aclarion, Inc. has been named a finalist in the Rising Star - Clinical Diagnostic Device category for the 2025 Digital Health Hub Foundation Awards. This recognition honors their breakthrough Nociscan solution, the first evidence-supported software platform to help physicians identify the source of chronic low back pain noninvasively. Nociscan uses MR spectroscopy to provide objective biomarkers and actionable insights, enabling more personali...
10-07 10:00
